RheumNow Live 2025

• Include: 37 videos, size: 22.78 GB
• Target Audience: rheumatologists and clinical immunologists
• Sample video: contact me for sample video
• Information:

1. Overview

Course Date: 2025

2. Learning Objectives

Evaluate the efficacy, safety, and clinical positioning of new biologic therapies, JAK inhibitors, and TYK2 inhibitors across various rheumatic diseases.

Implement advanced imaging techniques for the accurate evaluation and ongoing monitoring of spondyloarthritis and vasculitis.

Develop comprehensive management plans for rheumatoid arthritis, addressing disease flares, multimorbidity, and the unique considerations for older adults.

Assess aggressive treatment strategies in psoriasis to prevent psoriatic arthritis and analyze head-to-head clinical studies for optimal biologic selection.

Apply updated clinical guidelines for managing complex conditions like systemic lupus erythematosus (SLE), including new steroid protocols and the role of interferons.

3. Target Audience

Best for rheumatologists and clinical immunologists who want updates on biologic therapies, JAK inhibitors, RA multimorbidity, and vasculitis.

4. Topics

Adjourn

Advances in Treatment of Spondyloarthritis

AI applied to Rheumatoid Arthritis Care Practically Not Perfect

BIMZELX bimekizumab-bkzx Expert Perspectives on a New Treatment for PsA nr-axSpA and AS by Dr Evan Siegel

Can Aggressive Treatment of Psoriasis Prevent PsA

Combination Biologic Therapies in PsA

Dermatomyositis Updates Insights and JAK-Is too

Head-to-head Studies in Psoriatic Disease What have we learned

Imaging Evaluation of Spondyloarthritis

Imaging in Vasculitis

Interferons Role in SLE

JAK Faculty Panel Discussion with QA

JAK Inhibitors – POD III

Key Considerations Managing Older Adults with RA

KEYNOTE LECTURE Reinventing Oneself in Medicine

Management of EGPA in 2025 and Beyond

Modern Treatment of PMR

Multimorbidity in RA What to Do and Who Should Do It

Optimizing Care for PMR Advances and Challenges in Diagnosis and Treatment by Adam Brown MD Rheumatologist at C…

POD 7 Spondyloarthritis

POD I – Rheumatoid Arthritis

POD V Vasculitis

Progress in Hidradenitis Supprativa

Psoriatic Arthritis – POD II

Psoriatic Faculty Panel Discussion with QA

Rheumatoid Faculty Panel Discussion with QA

Spondyloarthritis Faculty Panel Discussion with QA

STEP Environmental Rheumatology

STEP Flares of Rheumatoid Arthritis

STEP Morphea and Linear Scleroderma

STEP New Steroid Rules for Lupus

STEP Oral Surveillance 3 years later

STEP Performance Art and Medicine

TYK2 Inhibitors Where do they fit

Vasculitis Faculty Panel Discussion with QA

Welcome Introductions

When JAKs Go Generic